Introduction: Interleukin (IL)-17 inhibitors are the most recent class of monoclonal antibodies
INTRODUCTION
Psoriasis is a common chronic immune-mediated skin disease that occurs in 3-4% of the adult US population [1] . Symptoms of psoriasis, which include redness, scaling, flaking, pruritus, skin tightness, pain, and bleeding, have a significantly negative impact on patients' physical and mental functioning [2] . Psoriasis also leads to impairment of quality of life, psychological well-being, and work productivity [2, 3] . Despite the rapid development of novel treatment modalities over the past 2 decades, surveys conducted by the National Psoriasis Foundation reveal that a significant portion of patients with psoriasis remain undertreated relative to the severity of their disease [3] . These patients will require new medications with superior long-term efficacy and safety for the treatment of moderate-to-severe psoriasis.
Brodalumab is one of three biologic agents, in addition to secukinumab and ixekizumab, which targets the interleukin (IL)-17 cytokine pathway, which has been implicated in the pathogenesis of psoriasis. IL-17A is one of six subsets of IL-17 and is regarded as the most significant subtype in psoriasis development [4, 5] . The cytokine applies its effect by binding the IL-17 receptor type A (IL-17RA) [6] . TH17 cells are increased in psoriatic lesions and are activated by IL-23 to release IL-17 [7] [8] [9] [10] [11] . IL-17 plays a part in the stimulation and recruitment of neutrophils, the defense of neutrophil apoptosis, and the provocation of psoriasis angiogenesis [5, [12] [13] [14] . Proof of increased levels of IL-17 mRNA [15] and IL-17 in psoriatic lesions and in the serum of psoriasis patients further supports the role of IL-17 in the pathogenesis of psoriasis [8, [16] [17] [18] [19] .
Brodalumab is a human immunoglobulin G (IgG) 2 monoclonal antibody that acts by specifically inhibiting IL-17RA, thus decreasing the downstream effect of IL-17 [20] . It binds with high affinity to IL-17RA and blocks the biological activity of IL-17A, IL-17F, and IL-25
(IL-17E) [20] .
In the following article, we review the results of the clinical phase III trials establishing the efficacy and safety of brodalumab in patients with moderate-to-severe plaque psoriasis. Two co-primary end points were examined: a 75% reduction in the Psoriasis Area and Severity 
METHODS
We conducted a systematic English-language literature search of PubMed, MEDLINE, and 
RESULTS
Three major phase III clinical trials, AMAGINE-1, AMAGINE-2, and AMAGINE-3 (ClinicalTrials.gov identifiers: NCT01708590, NCT01708603, and NCT01708629, respectively), were conducted to determine the efficacy and safety of different doses of brodalumab compared to placebo [20, 21] . AMAGINE-2 and AMAGINE-3 also compared brodalumab to ustekinumab. The comparisons in baseline demographics are shown in Table 1, while the results from each of these trials are displayed in Table 2 . All three trials were eventually terminated prematurely by the study sponsor (Amgen) prior to obtaining long-term extension data.
AMAGINE-1

Study Design
This was a randomized, double-blind, placebo-controlled multicenter trial that consisted of 661 patients randomly distributed in a 1:1:1 ratio to receive 210 mg brodalumab, 140 mg brodalumab, or placebo (all given as a subcutaneous injection on day 1 and weeks 1, 2, 4, 6, 8, and 10) [20] . The study incorporated the co-primary end points of PASI 75 and sPGA 0 or 1 at week 12. PASI 90, PASI 100, and Psoriasis Symptom Inventory (PSI) response were included as secondary end points in the study.
The PSI is a patient-performed symptom self-assessment that measures psoriasis signs and symptoms. At 12 weeks, patients receiving brodalumab were re-randomized to receive placebo, brodalumab 210 mg, or brodalumab 140 mg every 2 weeks (Q2W) through week 52. 
Efficacy
Adverse Events
At 12 weeks, a greater proportion of patients receiving brodalumab 210 mg and brodalumab 140 mg experienced any treatment-related adverse events (59% and 57.5%, respectively) or serious adverse events (1.8% and 2.7%, Table 1 Baseline demographics and clinical characteristics for all patients enrolled in the AMAGINE-2 and AMAGINE-3 studies 161 (73) 162 (74) 161 (73) 219 (71) 205 (68) 413 (68) 421 (69) 208 (66) 212 (68) 437 (70) 431 (69) White race, no. 196 (90) 2013 (91) 273 (88) 271 (90) 557 (91) 551 (90) 294 (93) 280 (90) 569 (91) 565 ( 63 (29) 60 (27) 58 (26) 51 (17) 50 (17) 125 (21) 114 (19) 59 (19) 64 (20) 134 (21) 127 (20) Body-surface area involved, % 129 (59) 121 (55) 167 (54) 153 (51) 358 (59) 316 (52) 192 (61) 192 (61) 412 (66) 373 (60) 4 91 (41) 80 (37) 87 (39) 120 (39) 132 (44) 217 (36) 254 (42) 113 (36) 103 (33) 192 (31) 226 (36) 5 (very severe)
15 (7) 10 (5) 14 (6) 22 (7) 15 (5) 35 (6) 42 (7) 10 (3) 18 (6) 25 (4) 25 (4) PSI score 225 (75) 471 (77) 469 (77) 206 (65) 220 (70) 439 (70) 422 (68) Previous biologic therapy, no. (%)
101 (46) 99 (45) 105 (47) 90 (29) 84 (28) 179 (29) 177 (29) 76 (24) 75 (24) 160 (25) 157 (25) Plus-minus values are mean ± 
AMAGINE-2
Study Design
This was a randomized, double-blind, placebo-controlled, parallel group multicenter trial that consisted of 1831 patients randomly distributed in a 2:2:1:1 ratio to receive either brodalumab 210 mg or brodalumab 140 mg (both given as a subcutaneous injection on 
Adverse Events
The pooled proportion of patients who experienced adverse events at 12 weeks in all three studies was 57.6% among patients taking (Table 2 ). Based on evidence that patients who reach PASI 90 or PASI 100 experience greater improvement in quality of life than PASI 75 responders [22] , we can estimate that these efficacy achievements are more significant than PASI 75 from a patient perspective. In comparison to secukinumab and ixekizumab, brodalumab achieves similar treatment results at 12 weeks. However, brodalumab appears to deliver greater PASI 100 rates at 12 weeks and better overall maintenance at 52 weeks, although no head-to-head studies have been conducted and research is still in its early states [23] . In any case, the development of this unique, highly effective class of biologic therapy provides optimism for patients whose psoriasis remains refractory to older biologic agents. Candida infections were more common among patients taking brodalumab than in those taking placebo among the studies we examined. In comparison to secukinumab and ixekizumab, no substantial differences were noted in the safety profile, with nasopharyngitis, upper respiratory infection, and headache comprising the most common adverse events [23] . Both neutropenia and candida infections generally occurred more frequently, although not significantly, in patients on the three therapeutics. Of utmost significance, the AMAGINE-2 trial included two patients who completed suicide (one within 52 weeks and another one beyond 52 weeks) while on brodalumab. Although concerning, these events do not necessarily constitute a causative relationship between brodalumab and suicidal ideation, especially given that patients with psoriasis are already at higher risk for depression, suicidal ideation, suicide attempt, and completed suicide [26, 27] . Regardless, Amgen, the company involved in the devlopment of brodalumab, has decided to withdraw from co-development of the drug because of worries of a potential black box warning about suicide, citing ''events of suicidal ideation and behavior in the brodalumab program'' [19] . Valeant Pharmaceuticals has since assumed a lead role in the further development of brodalumab [28] .
Brodalumab is a human IgG2 monoclonal antibody that may better achieve full clearance (PASI 100) relative to the other IL-17A cytokine specific agents, secukinumab and ixekizumab, because it is the only treatment in development that inhibits the IL-17 receptor (IL-17RA).
Although IL-17A is recognized as the most significant IL-17 isotype in the pathogenesis of psoriasis [5] , IL-17F and IL-25 also interact with the IL-17 receptor to provoke inflammatory signaling [4, 20] In addition to treating psoriasis, brodalumab has the potential to offer further systemic benefits. With regards to psoriatic arthritis, which affects between 5% and 30% of those with psoriasis, anti-IL-17 agents may have a critical role, as higher levels of IL-17 and IL-17RA have been observed within the synoviocytes and synovial fluid of psoriatic arthritis patients [30] [31] [32] [33] . Consequently, a phase III clinical trial has shown that brodalumab was statistically superior to placebo in the treatment of patients with active psoriatic arthritis at 12 weeks, as measured by the proportion of patients achieving an American College of Rheumatology 20% improvement response (ACR20) and 50% improvement response (ACR50) [34] . Brodalumab is also being tested as a treatment for asthma and axial spondyloarthritis [35, 36] . Additionally, treatment of the inflammatory state underlying psoriasis has the ability to reduce the incidence of cardiovascular disease [37] .
Increased IL-17 has been detected in atherosclerotic plaques [38] and is believed to pair with other inflammatory signals in forming plaques [39] . These observations together convey the possibility of using IL-17 pathway antagonists to treat not only psoriasis, but also psoriatic arthritis and to reduce the risk of cardiovascular disease in those with psoriasis [40] .
CONCLUSION
Brodalumab has generated encouraging data for efficacy and safety in the treatment of chronic plaque psoriasis. 13. Kao C-YY, Chen Y, Thai P, et al. IL-17 markedly up-regulates beta-defensin-2 expression in human
